NCT03424018ACTIVE_NOT_RECRUITINGanonymous

A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia

Sponsor

Source record

BioMarin Pharmaceutical

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

BMN 111

Indication / condition

AI-normalized

Achondroplasia

Intervention

Source record

BMN 111

Related intelligence directories

Indication directory: Achondroplasia Modality directory: small molecule Target directory: BMN 111

Source & freshness

Source record

NCT ID

NCT03424018

Original source

ClinicalTrials.gov

Source last updated

Mar 13, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03424018

Title

A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia

Sponsor

BioMarin Pharmaceutical

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE3

Condition raw

Achondroplasia

Condition normalized

Achondroplasia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

BMN 111

Target normalized

BMN 111

Interventions

BMN 111

Public preview

Source record

The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03424018

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE3

Sponsor

BioMarin Pharmaceutical

Executive brief

Investment-Ready Snapshot

The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMar 13, 2026

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03424018

Indication

Achondroplasia

Modality

small molecule

Target

BMN 111

Intervention

BMN 111

Source record